Table 2 Common genomic aberrations and their detection rates using the custom capture next-generation sequencing (NGS) assay and fluorescent in situ hybridization (FISH) and single-nucleotide polymorphism (SNP) microarray, respectively.

From: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma

Aberration

FISH/SNP microarray and NGS assay

FISH/SNP microarray Unique

NGS assay Unique

Sensitivity, % (95% CI*)

Specificity, % (95% CI*)

Overall

483

6

15

0.99 (0.97–1)

0.99 (0.99–1)

Del(1p)

28

1

0

0.97 (0.82–1)

1 (0.97–1)

Gain(1q)

55

1

0

0.98 (0.9–1)

1 (0.96–1)

Del(6q)

35

1

2

0.97 (0.85–1)

0.98 (0.94–1)

Del(8p)

33

0

2

1 (0.89–1)

0.98 (0.94–1)

Del(13q)

77

1

0

0.99 (0.93–1)

1 (0.95–1)

Del(14q)

40

0

5

1 (0.91–1)

0.96 (0.9–0.99)

Del(16q)

42

0

3

1 (0.92–1)

0.97 (0.93–0.99)

Del(17p)

26

0

2

1 (0.87–1)

0.98 (0.95–1)

HRD

73

0

0

1 (0.95–1)

1 (0.96–1)

t(4;14)

13

0

0

1 (0.75–1)

1 (0.97–1)

t(6;14)

1

0

0

1 (0.03–1)

1 (0.98–1)

t(8;14)

8

2

1

0.8 (0.44–0.97)

0.99 (0.96–1)

t(11;14)

48

0

0

1 (0.93–1)

1 (0.97–1)

t(14;16)

2

0

0

1 (0.16–1)

1 (0.98–1)

t(14;20)

2

0

0

1 (0.16–1)

1 (0.98–1)

  1. FISH fluorescent in situ hybridization, SNP single-nucleotide polymorphism, NGS next-generation sequencing, CI confidence interval, HRD hyperdiploidy